{
    "clinical_study": {
        "@rank": "51810", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp BID +/- OADs", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg OD plus IAsp +/- OADs", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, Europe and the United States of America (USA).\n\n      The aim of the trial is to compare the difference in change in glycosylated haemoglobin\n      (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs\n      (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs."
        }, 
        "brief_title": "A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of type 2 Diabetes Mellitus at the discretion of the investigator for at\n             least 26 weeks prior to screening (visit 1)\n\n          -  Treatment with basal insulin for at least 12 weeks prior to randomisation with or\n             without metformin, sulphonylurea (SU)/glinide, DPP-4 inhibitors,\n             alfa-glucosidase-inhibitors\n\n          -  HbA1c 7.0% - 10.0%\n\n          -  Body mass index (BMI) less than or equal to 40.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Treatment with glucose-lowering agent(s) other than those stated in the inclusion\n             criteria\n\n          -  Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial\n             infarction; unstable angina pectoris; or coronary arterial bypass graft or\n             angioplasty\n\n          -  Chronic disorder or disease which might jeopardise safety or compliance\n\n          -  Malignant neoplasms\n\n          -  Recurrent severe hypoglycaemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "274", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713530", 
            "org_study_id": "NN5401-3996", 
            "secondary_id": [
                "2012-002346-20", 
                "U1111-1130-7135"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "IDegAsp BID +/- OADs", 
                "description": "Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.", 
                "intervention_name": "insulin degludec/insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDeg OD plus IAsp +/- OADs", 
                "description": "Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDeg OD plus IAsp +/- OADs", 
                "description": "Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mission Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91345"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92111"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kissimmee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34741"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46254"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slidell", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70461-4231"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20852"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buckley", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49620"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hillsborough", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08844-1225"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08648"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toms River", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08755-8050"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27408"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Whiteville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28472"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15236"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingsport", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37660"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Round Rock", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78681"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78224"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Martinsburg", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "25401"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Algiers", 
                        "country": "Algeria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Creusot", 
                        "country": "France", 
                        "zip": "71200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kongsvinger", 
                        "country": "Norway", 
                        "zip": "2212"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Algeria", 
                "Austria", 
                "France", 
                "Norway"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Algeria: Ministry of Health", 
                "Austria: Agency for Health and Food Safety", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Norway: Norwegian Medicines Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c (%)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713530"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Number of treatment emergent hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Number of treatment emergent hypoglycaemic episodes. Number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }, 
            {
                "measure": "Incidence of treatment emergent adverse events (TEAE)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}